Stryker Corporation $SYK Stock Purchased by Valley National Advisers Inc.

Valley National Advisers Inc. boosted its position in shares of Stryker Corporation (NYSE:SYK) by 48.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,442 shares of the medical technology company’s stock after purchasing an additional 2,748 shares during the quarter. Valley National Advisers Inc.’s holdings in Stryker were worth $2,325,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new position in shares of Stryker in the 2nd quarter valued at about $1,404,284,000. Legal & General Group Plc acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $707,212,000. Jupiter Topco LLC bought a new stake in shares of Stryker during the second quarter worth approximately $681,581,000. Corient Private Wealth LP bought a new stake in shares of Stryker during the second quarter worth approximately $323,035,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Stryker during the second quarter worth approximately $464,506,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 351,267 shares of company stock valued at $118,197,701 in the last 90 days. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Piper Sandler cut their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Citigroup lowered their target price on shares of Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a report on Thursday, September 10th. Citizens Jmp dropped their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Finally, UBS Group initiated coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $369.00.

Stryker Trading Up 0.2%

NYSE:SYK opened at $307.65 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The firm has a market capitalization of $118.01 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 1.98 and a beta of 0.78. The business’s 50-day moving average price is $295.23 and its two-hundred day moving average price is $311.93.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.